Third Akorn sterile drug plant hit by FDA as new CEO lays out blueprint for a better future
Akorn Pharmaceuticals, which had a $ 4.3 billion buyout by Fresenius tank last fall, just can’t seem to catch a break. Just weeks after being hit with an FDA warning letter for its manufacturing operations in Illinois—problems that led to the death of the deal—Akorn today reported that it has received a citation on its third… Read More »